Champions Oncology Stock EBITDA

CSBR Stock

USD 4.31 0.02 0.46%

Champions Oncology fundamentals help investors to digest information that contributes to Champions Oncology's financial success or failures. It also enables traders to predict the movement of Champions Stock. The fundamental analysis module provides a way to measure Champions Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Champions Oncology stock.

		Last Reported	Projected for Next Year
	EBITDA	-5.1 M	-4.8 M

As of 11/29/2024, EBITDA is likely to grow to about (4.8 M).

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Champions Oncology Company EBITDA Analysis

Champions Oncology's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Champions Oncology EBITDA

(5.05 M)

Most of Champions Oncology's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Champions Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Champions EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for Champions Oncology is extremely important. It helps to project a fair market value of Champions Stock properly, considering its historical fundamentals such as EBITDA. Since Champions Oncology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Champions Oncology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Champions Oncology's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Common Stock	Long Term Debt	Short Term Debt	Property Plant Equipment	Current Deferred Revenue	Intangible Assets	Good Will	Treasury Stock	Deferred Long Term Liab	Net Tangible Assets	Capital Surpluse	Net Invested Capital	Short Long Term Debt	Net Working Capital	Long Term Debt Total	Capital Stock
Total Assets		0.38	0.51	-0.67	0.73	0.91	0.92	0.96	-0.2	-0.11	0.87	0.93	0.89	0.41	-0.91	-0.35	0.46	0.7	0.74	0.57	-0.75	-0.05	-0.36	0.79
Total Stockholder Equity	0.38		-0.29	-0.1	-0.2	0.09	0.0	0.5	0.27	0.17	-0.01	0.12	0.02	0.09	-0.27	-0.19	0.21	0.6	0.1	0.68	-0.09	0.61	0.4	-0.08
Net Debt	0.51	-0.29		-0.49	0.57	0.75	0.68	0.26	-0.6	-0.19	0.66	0.77	0.67	-0.05	-0.61	0.18	0.22	0.19	0.64	0.12	-0.66	-0.36	-0.58	0.69
Retained Earnings	-0.67	-0.1	-0.49		-0.75	-0.79	-0.69	-0.62	0.32	-0.21	-0.6	-0.67	-0.79	-0.67	0.61	0.59	-0.29	-0.19	-0.93	-0.25	0.77	0.18	0.37	-0.6
Accounts Payable	0.73	-0.2	0.57	-0.75		0.85	0.88	0.68	-0.28	-0.03	0.89	0.81	0.91	0.46	-0.68	-0.32	0.31	0.23	0.77	-0.04	-0.73	-0.59	-0.72	0.87
Net Receivables	0.91	0.09	0.75	-0.79	0.85		0.94	0.79	-0.38	-0.13	0.91	0.96	0.96	0.38	-0.85	-0.26	0.44	0.5	0.86	0.35	-0.88	-0.28	-0.58	0.88
Total Liab	0.92	0.0	0.68	-0.69	0.88	0.94		0.83	-0.32	-0.19	0.94	0.96	0.95	0.41	-0.87	-0.3	0.41	0.51	0.76	0.33	-0.77	-0.31	-0.56	0.89
Total Current Assets	0.96	0.5	0.26	-0.62	0.68	0.79	0.83		-0.01	-0.05	0.79	0.81	0.8	0.5	-0.82	-0.46	0.45	0.72	0.64	0.55	-0.64	0.0	-0.28	0.7
Common Stock	-0.2	0.27	-0.6	0.32	-0.28	-0.38	-0.32	-0.01		0.42	-0.25	-0.34	-0.36	0.14	0.35	-0.18	0.08	0.29	-0.43	-0.25	0.48	-0.05	0.07	-0.26
Long Term Debt	-0.11	0.17	-0.19	-0.21	-0.03	-0.13	-0.19	-0.05	0.42		-0.1	-0.14	-0.05	0.11	0.18	-0.13	-0.38	0.11	0.16	-0.16	0.23	-0.06	-0.02	-0.11
Short Term Debt	0.87	-0.01	0.66	-0.6	0.89	0.91	0.94	0.79	-0.25	-0.1		0.94	0.95	0.26	-0.81	-0.12	0.37	0.49	0.7	0.15	-0.68	-0.48	-0.68	0.95
Property Plant Equipment	0.93	0.12	0.77	-0.67	0.81	0.96	0.96	0.81	-0.34	-0.14	0.94		0.93	0.29	-0.91	-0.17	0.42	0.59	0.78	0.37	-0.79	-0.28	-0.59	0.91
Current Deferred Revenue	0.89	0.02	0.67	-0.79	0.91	0.96	0.95	0.8	-0.36	-0.05	0.95	0.93		0.4	-0.81	-0.28	0.38	0.4	0.84	0.25	-0.78	-0.38	-0.59	0.89
Intangible Assets	0.41	0.09	-0.05	-0.67	0.46	0.38	0.41	0.5	0.14	0.11	0.26	0.29	0.4		-0.27	-0.96	0.26	0.11	0.46	0.07	-0.33	-0.12	-0.14	0.3
Good Will	-0.91	-0.27	-0.61	0.61	-0.68	-0.85	-0.87	-0.82	0.35	0.18	-0.81	-0.91	-0.81	-0.27		0.16	-0.43	-0.67	-0.76	-0.56	0.77	0.04	0.32	-0.82
Treasury Stock	-0.35	-0.19	0.18	0.59	-0.32	-0.26	-0.3	-0.46	-0.18	-0.13	-0.12	-0.17	-0.28	-0.96	0.16		-0.23	-0.07	-0.34	-0.17	0.24	-0.08	0.01	-0.09
Deferred Long Term Liab	0.46	0.21	0.22	-0.29	0.31	0.44	0.41	0.45	0.08	-0.38	0.37	0.42	0.38	0.26	-0.43	-0.23		0.33	0.22	0.29	-0.39	0.03	-0.18	0.35
Net Tangible Assets	0.7	0.6	0.19	-0.19	0.23	0.5	0.51	0.72	0.29	0.11	0.49	0.59	0.4	0.11	-0.67	-0.07	0.33		0.34	0.59	-0.36	0.21	-0.11	0.48
Capital Surpluse	0.74	0.1	0.64	-0.93	0.77	0.86	0.76	0.64	-0.43	0.16	0.7	0.78	0.84	0.46	-0.76	-0.34	0.22	0.34		0.33	-0.85	-0.18	-0.37	0.73
Net Invested Capital	0.57	0.68	0.12	-0.25	-0.04	0.35	0.33	0.55	-0.25	-0.16	0.15	0.37	0.25	0.07	-0.56	-0.17	0.29	0.59	0.33		-0.39	0.78	0.43	0.07
Short Long Term Debt	-0.75	-0.09	-0.66	0.77	-0.73	-0.88	-0.77	-0.64	0.48	0.23	-0.68	-0.79	-0.78	-0.33	0.77	0.24	-0.39	-0.36	-0.85	-0.39		0.12	0.37	-0.69
Net Working Capital	-0.05	0.61	-0.36	0.18	-0.59	-0.28	-0.31	0.0	-0.05	-0.06	-0.48	-0.28	-0.38	-0.12	0.04	-0.08	0.03	0.21	-0.18	0.78	0.12		0.8	-0.54
Long Term Debt Total	-0.36	0.4	-0.58	0.37	-0.72	-0.58	-0.56	-0.28	0.07	-0.02	-0.68	-0.59	-0.59	-0.14	0.32	0.01	-0.18	-0.11	-0.37	0.43	0.37	0.8		-0.68
Capital Stock	0.79	-0.08	0.69	-0.6	0.87	0.88	0.89	0.7	-0.26	-0.11	0.95	0.91	0.89	0.3	-0.82	-0.09	0.35	0.48	0.73	0.07	-0.69	-0.54	-0.68

Click cells to compare fundamentals

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict Champions Oncology

Ebitda Over Time

Champions Ebitda

Ebitda

(4.8 Million)

Champions Oncology reported last year EBITDA of (5.05 Million)

According to the company disclosure, Champions Oncology reported earnings before interest,tax, depreciation and amortization of (5.05 Million). This is 100.58% lower than that of the Life Sciences Tools & Services sector and 105.05% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.13% higher than that of the company.

Champions EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Champions Oncology's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Champions Oncology could also be used in its relative valuation, which is a method of valuing Champions Oncology by comparing valuation metrics of similar companies.

Champions Oncology is currently under evaluation in ebitda category among its peers.

Champions Oncology Current Valuation Drivers

We derive many important indicators used in calculating different scores of Champions Oncology from analyzing Champions Oncology's financial statements. These drivers represent accounts that assess Champions Oncology's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Champions Oncology's important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	91.4M	141.0M	101.4M	65.8M	65.7M	46.0M
Enterprise Value	86.9M	145.9M	101.8M	64.3M	70.5M	44.4M

Champions Oncology ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Champions Oncology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Champions Oncology's managers, analysts, and investors.

Environmental

Governance

Social

Champions Oncology Institutional Holders

Institutional Holdings refers to the ownership stake in Champions Oncology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Champions Oncology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Champions Oncology's value.

		Shares
Bank Of New York Mellon Corp	2024-06-30	26.7 K
State Street Corp	2024-06-30	26.6 K
Bank Of America Corp	2024-06-30	25.3 K
Cambridge Invest Research Advisors, Inc.	2024-09-30	12.3 K
Mesirow Fin Investmt Mgmt Intl Equity	2024-09-30	12 K
Stifel Financial Corp	2024-06-30	10.9 K
Simplex Trading, Llc	2024-06-30	3 K
Ubs Group Ag	2024-06-30	379
Royal Bank Of Canada	2024-06-30	133
Battery Management Corp	2024-09-30	2.4 M
Nea Management Company, Llc	2024-06-30	1.7 M

Champions Fundamentals

	Return On Equity	-4.32
	Return On Asset	-0.0693
	Profit Margin	(0.07) %
	Operating Margin	0.09 %
	Current Valuation	62.8 M
	Shares Outstanding	13.59 M
	Shares Owned By Insiders	26.33 %
	Shares Owned By Institutions	49.00 %
	Number Of Shares Shorted	224.45 K
	Price To Earning	220.00 X
	Price To Book	6.77 X
	Price To Sales	1.13 X
	Revenue	50.16 M
	Gross Profit	24.34 M
	EBITDA	(5.05 M)
	Net Income	(7.28 M)
	Cash And Equivalents	8.06 M
	Cash Per Share	0.60 X
	Total Debt	7.43 M
	Debt To Equity	1.03 %
	Current Ratio	1.11 X
	Book Value Per Share	(0.02) X
	Cash Flow From Operations	(6.14 M)
	Short Ratio	18.41 X
	Earnings Per Share	(0.26) X
	Target Price	6.0
	Number Of Employees	210
	Beta	0.49
	Market Capitalization	58.59 M
	Total Asset	26.13 M
	Retained Earnings	(84.59 M)
	Working Capital	(7.9 M)
	Current Asset	4.34 M
	Current Liabilities	5.31 M
	Net Asset	26.13 M

About Champions Oncology Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Champions Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Champions Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Champions Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Pair Trading with Champions Oncology

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Champions Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Champions Oncology will appreciate offsetting losses from the drop in the long position's value.

Moving against Champions Stock

0.49	VERV	Verve Therapeutics	Pair Corr
0.46	DRUG	Bright Minds Biosciences	Pair Corr
0.36	EQ	Equillium	Pair Corr
0.35	VANI	Vivani Medical	Pair Corr

The ability to find closely correlated positions to Champions Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Champions Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Champions Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Champions Oncology to buy it.

The correlation of Champions Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Champions Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Champions Oncology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Champions Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Champions Stock Analysis

When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC